ClinicalTrials.gov record
Recruiting Phase 4 Interventional

Asciminib Roll-over Study

ClinicalTrials.gov ID: NCT04877522

Public ClinicalTrials.gov record NCT04877522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment

Study identification

NCT ID
NCT04877522
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
347 participants

Conditions and interventions

Interventions

  • Asciminib single agent Drug
  • Asciminib single agent pediatric formulation Drug
  • Bosutinib Drug
  • Dasatinib Drug
  • Imatinib Drug
  • Nilotinib Drug

Drug

Eligibility (public fields only)

Age range
7 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 29, 2022
Primary completion
Aug 28, 2030
Completion
Aug 29, 2030
Last update posted
Mar 5, 2026

2022 – 2030

United States locations

U.S. sites
5
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
Michigan Med University of Michigan Ann Arbor Michigan 48109 5271 Recruiting
Memorial Sloan Kettering New York New York 10017 Recruiting
Oregon Health Sciences University Portland Oregon 97239 Active, not recruiting
Texas Oncology Dallas Texas 75251 Recruiting
Uni Of TX MD Anderson Cancer Cntr Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04877522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04877522 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →